Treatment of reduced bone density with ibandronate in dialysis patients

Journal of Nephrology

Volumn 21, Issue 4, 2008, Pages 510-516

  Bergner, Raoul ^a   Henrich, Dirk ^a   Hoffmann, Martin ^a   Schmidt Gayk, Heinrich ^b   Lenz, Tomas ^c   Uppenkamp, Michael ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b Limbach Laboratory   (Germany)

^c Kuratorium für Hämodialyse und Nierentransplantation e V   (Germany)

Author keywords

Bisphosphonates; Bone alkaline phosphatase; Crosslaps; Ibandronate; Renal osteodystrophy

Indexed keywords

CALCITRIOL; CALCIUM; HYDROXYAPATITE; IBANDRONIC ACID; MAGNESIUM; PARACETAMOL; PARATHYROID HORMONE; PHOSPHATE; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; LUMBAR SPINE; MAGNESIUM BLOOD LEVEL; MALE; MORTALITY; MYALGIA; NORMAL VALUE; OPEN STUDY; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PATIENT SELECTION; PHOSPHATE BLOOD LEVEL; RENAL OSTEODYSTROPHY; SCORING SYSTEM; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; LUMBAR VERTEBRA; METABOLISM; METHODOLOGY; MIDDLE AGED; PHOTON ABSORPTIOMETRY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; TREATMENT OUTCOME;

EID: 52649155136     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res. 2002;17:2094-2105.
2. Locatelli F, Cannata-Andia JB, Drueke TB, et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant. 2002;17:723-731.
3. Brandenburg VM, Westenfeld R, Ketteler M. The fate of bone after renal transplantation. J Nephrol. 2004;17:190-204.
4. Haas M. Renal osteodystrophy. Wien Med Wochenschr. 2004;154:107-118.
5. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Available at: http://www.kidney.org/professionals/kdoqi/guidelines_bp/. Accessed July 4, 2008.
6. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165-176.
7. Krempien R, Niethammer A, Harms W, Debus J. Bisphosphonates and bone metastases: current status and future directions. Expert Rev Anticancer Ther. 2005;5:295-305.
8. McClung M. Use of highly potent bisphosphonates in the treatment of osteoporosis. Curr Osteoporos Rep. 2003;1:116-122.
9. Mathoo JM, Cranney A, Papaioannou A, Adachi JD. Rational use of oral bisphosphonates for the treatment of osteoporosis. Curr Osteoporos Rep. 2004;2:17-23.
10. Reginster JY. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Curr Pharm Des. 2005;11:3711-3728.
11. Grotz W, Nagel C, Poeschel D, et al. Effect of Ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001;12:1530-1537.
12. Haas M, Leko-Mohr Z, Roschger P, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int. 2003;63:1130-1136.
13. Cohen A, Sambrook P, Shane E. Management of bone loss after organ transplantation. J Bone Miner Res. 2004;19:1919-1932.
14. Malluche HH. The possible use of bisphosphonates in the treatment of renal osteodystrophy. Clin Nephrol. 1992;38(Suppl 1):S87-91.
15. Fan SL, Cunningham J. Bisphosphonates in renal osteodystrophy. Curr Opin Nephrol Hypertens. 2001;10:581-588.
16. Rodd C. Bisphosphonates in dialysis and transplantation patients: efficacy and safety issues. Perit Dial Int. 2001;21(Suppl 3):S256-260.
17. Hamdy NA, McCloskey EV, Brown CB, Kanis J. Effects of clodronate in severe hyperparathyroid bone disease in chronic renal failure. Nephron. 1990;56:6-12.
18. Torregrosa JV, Moreno A, Mas M, Ybarra J, Fuster D. Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. Kidney Int Suppl. 2003;63(Suppl 85):S88-S90.
19. Diel IJ. Ibandronate: efficacy in the treatment of metastatic bone disease. Future Oncol. 2005;1:593-607.
20. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14:1399-1405.
21. Bergner R, Dill K, Boerner D, Uppenkamp M. Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. Nephrol Dial Transplant. 2002;17:1281-1285.
22. Beigel AE, Rienhoff E, Olbricht CJ. Removal of clodronate by haemodialysis in end-stage renal disease patients. Nephrol Dial Transplant. 1995;10:2266-2268.
23. Ala-Houhala I, Saha H, Liukko-Sipi S, Ylitalo P, Pasternack A. Pharmacokinetics of clodronate in haemodialysis patients. Nephrol Dial Transplant. 1999;14:699-705.
24. Price PA, Buckley JR, Williamson MK. The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. Nutrition. 2001;131:2910-2915.
25. Geng Z, Monier-Faugere MC, Bauss F, Malluche HH. Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. Clin Nephrol. 2000;54:45-53.
26. Bergner A, Henrich D, Hoffmann M, et al. High bone-binding capacity of ibandronate in haemodialysis patients. Int J Clin Pharmacol Res. 2005;25:123-131.
27. Saha H, Ala-Houhala I, Ylitalo P, Kleimola T, Pasternack A. Skeletal deposition of clodronate is related to parathyroid function and bone turnover in dialysis patients. Clin Nephrol. 2002;58:47-53.
28. Chan TM, Pun KK, Cheng IK. Total and regional bone densities in dialysis patients. Nephrol Dial Transplant. 1992;7:835-839.
29. Karantanas AH, Kalef-Ezra JA, Sferopoulos G, Siamopoulos KC. Quantitative computed tomography for spinal bone mineral measurements in chronic renal failure. Br J Radiol. 1996;69:132-136.
30. Gabay C, Ruedin P, Slosman D, Bonjour JP, Leski M, Rizzoli R. Bone mineral density in patients with end-stage renal failure. Am J Nephrol. 1993;13:115-123.
31. Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G. Fracture and bone mineral density in hemodialysis patients. Clin Nephrol. 2000;54:218-226.
32. Urena P, Bernard-Poenaru O, Ostertag A, et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant. 2003;18:2325-2331.
33. Tomat A, Gamba GA, Mandalunis P, et al. Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease. J Musculoskelet Neuronal Interact. 2005;5:174-181.
34. Fletcher S, Jones RG, Rayner HG, et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron. 1997;75:412-419.
35. Chu P, Chao T-Y, Lin Y-F, Janckila AJ, Yam LT. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis. 2003;41:1052-1059.
36. Okuno S, Inaba M, Kitatani K, Ishimura E, Yamakawa T, Nishizawa Y. Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients. Osteoporos Int. 2005;16:501-509.
37. Heaf JG, Nielsen LP, Mogensen NB. Use of bone mineral content determination in the evaluation of osteodystrophy among hemodialysis patients. Nephron. 1983;35:103-107.
38. Taal MW, Masud T, Green D, Cassidy MJ. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant. 1999;14:1922-1928.
39. Gerakis A, Hadjidakis D, Kokkinakis E, Apostolou T, Raptis S, Billis A. Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol. 2000;13:437-443.
40. Ning JP, Sun M, Toru I, Etsuo Y. The relationship between bone mineral density and secondary hyperparathyroidism bone disease. Hunan Yi Ke Da Xue Xue Bao. 2000;25:77-79.
41. Pecovnik Balon B, Hojs R, Kos M. Bone mineral density in patients beginning hemodialysis treatment. Am J Nephrol. 2002;22:14-17.
42. Lu KC, Yeung LK, Lin SH, Lin YF, Chu P. Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 2003;42:1221-1227.